Rational Pharmacotherapy in Cardiology

Advanced search


Full Text:


Aim. To study the clinical and hemodynamic efficacy of monotherapy with ACE inhibitor perindopril or beta-blocker carvedilol in patients with chronic heart failure (CHF) due to dilated cardiomyopathy (DCMP) of various etiology.
Material and methods. Patients (n=69) with DCMP of different etiology were included into the open randomized study. Idiopathic DCMP (IDCMP) was diagnosed in 26 patients and alcoholic cardiomyopathy (ACMP) - in 43 patients. Patients of IDCMP and ACMP groups were randomized for treatment with perindopril (groups 1 and 3, respectively) or carvedilol (groups 2 and 4, respectively). Follow-up was 6 months. End-diastolic and end-systolic left ventricular volume, stroke volume index, ejection fraction (EF) and exercise capacity were determined at baseline and in 2 and 6 months of treatment. Safety of the treatments was also assessed.
Results. Group 1: the average CHF class (NYHA) decreased by 20.7% (p<0.01), EF increased by 18.2% (p<0.05). Group 2: the average CHF class decreased by 29.6% (p<0.01), EF increased by 18.2% (p<0.05). Group 3: the average CHF class decreased by 14.3% (p<0.01), EF increased by 19.6% (p<0.05). Group 4: the average CHF class decreased by 41.4% (p<0.001), EF increased by 32.8% (p<0.001).
Conclusion. Monotherapy with carvedilol in patients with ACMP was more effective than this with perindopril. Long-term monotherapy with perindopril or carvedilol in patients with DCMP was well tolerated and safety.

About the Authors

I. V. Zhirov
Russian Cardiology Research and Production Complex, Moscow
Russian Federation

G. K. Sarbalinova
Regional Hospital, Uralsk, West-Kazakstan Region, Kazakstan
Russian Federation

S. N. Tereschenko
Russian Cardiology Research and Production Complex, Moscow
Russian Federation


1. Ageyev FT, Danielian MO, Mareev VY et al. Patients with chronic heart failure in the Russian outpatient practice: the contingent features, diagnosis and treatment (studies of EPOHA-O-HSN). Serdechnaya Nedostatochnost 2003; (5): 4-8. Russian (Агеев Ф.Т., Даниелян М.О., Мареев В.Ю. и др. Больные с хронической сердечной недостаточностью в российской амбулаторной практике: особенности контингента, диагностики и лечения (по материалам исследования ЭПОХА-О-ХСН). Сердечная Недостаточность 2003; (5): 4-8).

2. Belenkov JN, Mareev VY, Ageyev FT et al. The first results of a national epidemiological study - epidemiological study of patients with chronic heart failure in the actual practice (uptake) - EPOHA-O-HSN. Serdechnaya Nedostatochnost 2003; (4): 116-21. Russian (Беленков Ю.Н., Мареев В.Ю., Агеев Ф.Т. и др. Первые результаты национального эпидемиологического исследования – эпидемиологическое обследование больных ХСН в реальной практике (по обращаемости) – ЭПОХА-О-ХСН. Сердечная Недостаточность 2003; (4): 116-21).

3. Hunt S., Gibbons R., Antman E. et al. Guidelines for the evaluation and management of chronic heart failure in the adult: Executive Summary. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. JACC 2001; 38: 2102-12.

4. Piano M. Alcoholic cardiomyopathy. Incidence, clinical characteristics and pathophysiology. Chest 2002; 121: 1638-50.

5. De Keulenaer GW, Brutsaert DL. Dilated cardiomyopathies: changing pathophysiological concepts and mechanisms of dysfunction. J Card Surg 1999; (4): 64-74.

6. Fauchier L. Alcoholic cardiomyopathy and ventricular arrhythmias. Chest 2003; 123: 1320-24.

7. Køber L, Torp-Pedersen C, Carlsen JE, et al. A clinical trial of the angiotensin-converting-enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. Trandolapril Cardiac Evaluation (TRACE) Study Group. N Engl J Med 1995; 333: 1670-77.

8. Lechat P., Packer M., Chalon S. et al. Beta-blockers in heart failure: meta-analysis of randomized trials. Circulation 1998; 1184-1191.

9. Crabbe S., Cleland J.G., Louis A. et al. Clinical trials update: CAPRICORN, COPERNICUS, MIRACLE, STAF, RITZ-2, RECOVER and RENAISSANCE and cachexia and cholesterol in heart failure. Highlights of the Scientific Sessions of the American College of Cardiology, 2001. Eur J Heart Fail 2001; 3: 381-387.

10. Dargie H. β-blockers in heart failure. Lancet 2003; 362: 2-3.

11. Richardson P. Report of the 1995 World Health Organization/International Society and Federation of Cardiology Task Force on the definition and classification of cardiomyopathies. Circulation 1995; 93: 841-2.

12. Moiseyev VS, editor. Rapid diagnosis (screening) of chronic alcohol intoxication in patients with somatic profile. Guidelines Ministry of Health number 99/174. Moscow: Russian Ministry of Health; 2001. Russian (Моисеев В.С., редактор. Экспресс-диагностика (скрининг) хронической алкогольной интоксикации у больных соматического профиля. Методические рекомендации Минздрава РФ №99/174. М: МЗ РФ; 2001).

13. Gillum RF. Heart failure in the United States, 1970-1985. Am Heart J 1987; 113: 1043-45.

14. Kasper E, Willem W, Hutchins G, et al. The causes of dilated cardiomyopathy: a clinicopathologic review of 673 consecutive patients. J Am Coll Cardiol 1994; 23: 586-90.

15. Fauchier L, Babuty D, Poret P, et al. Comparison of long-term outcome of alcoholic and idiopathic dilated cardiomyopathy. Eur Heart J 2000; 21: 306-14.

16. McKenna C, Codd M, McCann H, et al. Alcohol consumption idiopathic dilated cardiomyopathy: a case control study. Am Heart J 1998; 135: 833-7.

17. Gavazzi A, De Maria R, Parolini M, et al. On behalf of the Italian Multicenter Cardiomyopathy Study Group (SPIC) Alcohol abuse and cardiomyopathy in men. Am J Cardiol 2000; 85: 1114-18.

18. Detailed Diagnoses and Procedures, National Hospital Discharge Survey, 1993. Vital and Health Statistics 1995; 13(122): 1-294.

19. Fernández-Sol J, Estruch R, Nicol s J-M et al. Comparison of alcoholic cardiomyopathy in women versus men. Am J Cardiol 1997; 80: 481-48.

20. Mathews E, Gradin J, Henry W, et al. Echocardiographic abnormalities in chronic alcoholics with and without overt congestive heart failure. Am J Cardiol 1981; 47: 570-8.

21. Lazarevi A, Nakatani S, Nekovi A et al. Early changes in left ventricular function in chronic asymptomatic alcoholics: relation to the duration of heavy drinking. J Am Coll Cardiol 2000; 35: 1599-606.

22. Fernández-Sol J, Nicol s J, Par J, et al. Diastolic function impairment in alcoholics. Alcohol Clin Exp Med 2000; 24: 1830-35.

23. Kupari M, Koskinen P, Suokas A, et al. Left ventricular filling impairment in asymptomatic chronic alcoholics. Am J Cardiol 1990; 66: 1473-7.

24. Silberbauer K, Juhasz M, Ohrenberger G, et al. Noninvasive assessment of left ventricular diastolic function by pulsed Doppler echocardiography in young alcoholics. Cardiology 1988; 75: 431-9.

25. Askanas A, Udoshi M, Sadjadi S. The heart in chronic alcoholism: a noninvasive study. Am Heart J 1980; 99: 9-16.

26. Urbano-M rquez A, Estruch R, Navarro-Lopez F, et al. The effects of alcoholism on skeletal and cardiac muscle. N Engl J Med 1989; 320: 409-15.

27. Dancy M, Leech G, Bland J, et al. Preclinical left ventricular abnormalities in alcoholic are independent of nutritional status, cirrhosis and cigarette smoking. Lancet 1985; 1: 1122-5.

28. Kinny E, Wright R, Caldwell J. Risk factors in alcoholic cardiomyopathy. J Angiol Vasc Dis 1989; 4: 270-5.

29. Prazak P, Pfisterer M, Osswald S et al. Differences of disease progression in congestive heart failure due to alcoholic as compared to idiopathic cardiomyopathy. Eur Heart J 1996; 17: 251-7.

30. Bergstroem A, Andersson B, Edner M, et al. Carvedilol improves diastolic function in patients with diastolic heart failure. For the SWEDIC investigators. Circulation 2001; 104: 711-8.

31. Bristow MR, Gilbert EM, Abraham WT, et al. Carvedilol Produces Dose- Related Improvments in Left Ventricular Function and Survival in Subjects With Chronic Heart Failure. Circulation 1996; 11: 2807-16.

32. Di Lenarda, R. DeMaria, A.Gavazzi et al. Long-term survival effect of metoprolol in dilated cardiomyopathy. Heart 1998; 79: 337-44.

33. Packer M, Coats A, Flowler M, et al. Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med 2001; 344:1651-8.

34. Toyama T, Hoshizaki H, Seki R, et al. Efficacy of carvedilol treatment on cardiac function and cardiac sympathetic nerve activity in patients with dilated cardiomyopathy: comparison with metoprolol therapy. J Nucl Med 2003; 44: 1604-11.

35. Mann K., Bladstrom A., Torup L. et al. Extended the treatment options in alcohol dependence: a randomized controlled study of as-needed nalmefene. Biological Psychiatry 2013; 73:706-13.

For citation:


Views: 686

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.

ISSN 1819-6446 (Print)
ISSN 2225-3653 (Online)